Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

WR MCCR LLC

Neither a doctor nor a teaching hospital

Research payments

$1,587,423

104 payments

Through program year 2025, WR MCCR LLC is reported as receiving $1,587,423 in research payments, across 104 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $221,201 22
2024 Research $189,903 27
2023 Research $1,007,564 41
2022 Research $143,534 5
2021 Research $15,506 5
2020 Research $177 2
2019 Research $9,538 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bavarian Nordic A/S $744,552 18 payments
  2. Mylan Inc. $405,099 32 payments
  3. Moderna TX, Inc. $220,510 21 payments
  4. Merck Sharp & Dohme Corporation $131,534 3 payments
  5. Novavax Inc $37,630 11 payments
  6. Sebela Women's Health Inc. $20,025 6 payments
  7. Sebela Pharmaceuticals Inc. $15,506 5 payments
  8. Hexal AG $5,177 3 payments
  9. Ferring International Pharmascience Center US $4,538 1 payment
  10. GlaxoSmithKline, LLC. $2,852 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $732,552 16 payments
  2. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $405,099 32 payments
  3. A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $196,113 13 payments
  4. A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $93,962 1 payment
  5. A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines $37,630 11 payments
  6. A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age $37,572 2 payments
  7. A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability $35,532 11 payments
  8. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age $24,397 8 payments
  9. Nct05329220 $12,000 2 payments
  10. Cgp24112301 $5,177 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record